In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: CHRW's current price exceeds the PERT-weighted fair value by 15.3%, indicating potential overvaluation, reinforced by a high downside risk (97.2%) in Monte Carlo scenarios. Valuation variance is wide, with DCF suggesting lower value ($57.37 mid) versus P/E and analyst targets implying higher valuations. Strong financial health and growth contrast with valuation uncertainty and high volatility (CV 54.21%).